Morgan Stanley Homology Medicines, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.53 - $1.14 $6,920 - $14,886	13,058 New	13,058 $7,000
Q4 2023 Feb 13, 2024	BUY	$0.53 - $1.14 $41 - $88	78 Added 0.6%	13,058 $7,000
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.12 $120,825 - $163,041	-145,573 Reduced 91.81%	12,980 $11,000
Q1 2023 May 15, 2023	BUY	$0.91 - $1.69 $127,403 - $236,606	140,004 Added 754.78%	158,553 $163,000
Q4 2022 Feb 14, 2023	SELL	$1.09 - $2.04 $42,955 - $80,394	-39,409 Reduced 68.0%	18,549 $23,000
Q3 2022 Nov 14, 2022	SELL	$1.55 - $3.01 $75,272 - $146,174	-48,563 Reduced 45.59%	57,958 $93,000
Q2 2022 Oct 27, 2022	BUY	$1.39 - $3.12 $6,456 - $14,492	4,645 Added 4.56%	106,521 $210,000
Q2 2022 Aug 15, 2022	BUY	$1.39 - $3.12 $6,456 - $14,492	4,645 Added 4.56%	106,521 $210,000
Q1 2022 Oct 27, 2022	SELL	$2.6 - $4.17 $12,077 - $19,369	-4,645 Reduced 4.36%	101,876 $310,000
Q1 2022 May 13, 2022	SELL	$2.6 - $4.17 $453,128 - $726,747	-174,280 Reduced 63.11%	101,876 $310,000
Q4 2021 Feb 14, 2022	BUY	$3.64 - $7.78 $467,288 - $998,765	128,376 Added 86.87%	276,156 $1 Million
Q3 2021 Nov 15, 2021	BUY	$6.01 - $8.71 $888,157 - $1.29 Million	147,780 New	147,780 $1.16 Million

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.